Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of insulin-producing
ß cells. Although exogenous insulin is widely available, it is not possible for affected
individuals to consistently achieve euglycemia with current technology, and thus they are at
risk for devastating long-term complications. This phase II study is designed to evaluate the
safety and efficacy of imatinib mesylate as a novel therapy for new-onset T1DM. Imatinib is a
first-in-class tyrosine kinase inhibitor.
This study will explore the potential role of short-term therapy with imatinib to induce
tolerance and possibly lead to a durable long-term remission of T1DM.